Extended treatment with bupropion SR for cigarette smoking cessation.

Author(s): Killen JD, Fortmann SP, Murphy GM Jr, Hayward C, Arredondo C, Cromp D, Celio M, Abe L, Wang Y, Schatzberg AF

Affiliation(s): Stanford University School of Medicine, Stanford, CA 94305-5705, USA. jkillen@stanford.edu

Publication date & source: 2006-04, J Consult Clin Psychol., 74(2):286-94.

Publication type: Randomized Controlled Trial

The authors present results of a randomized clinical trial of the efficacy of extended treatment with bupropion SR in producing longer term cigarette smoking cessation. Adult smokers (N = 362) received open-label treatment (11 weeks) that combined relapse prevention training, bupropion SR, and nicotine patch followed by extended treatment (14 weeks) with bupropion SR or matching placebo. Abstinence percentages were relatively high (week 11: 52%; week 25: bupropion, 42%; placebo, 38%; week 52: bupropion, 33%; placebo, 34%), but bupropion SR did not surpass placebo. Gender and baseline craving level were identified as significant, independent moderators of treatment response. Men were more likely to abstain than women (week 11: 59% vs. 43%, p = .001; week 25: 48% vs. 31%, p = .001; week 52: 39% vs. 27%, p = .01). Because most smokers suffer relapse with any current cessation treatment, the comparatively high abstinence percentages achieved in this trial are of interest. Copyright 2006 APA